BridgeMD
New treatment option for Agitation
Official title Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
ClinicalTrials.gov ID: NCT05397639
What this study is testing
What is Masupirdine 50 mg?
Masupirdine 50 mg is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for agitation.
Also referred to as SUVN-502.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 to 90
You may be able to join if
- Has a diagnosis of dementia of the Alzheimer's type according to the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria.
- Has confirmed agitation using the IPA Consensus Provisional Definition of Agitation in Cognitive Disorders.
- Has a score between 8 and 24 (both inclusive) on Mini-Mental State Examination (MMSE).
You likely can't join if
- Participants with dementia predominantly of the non-Alzheimer's type (e.g., vascular dementia, parkinson's disease, lewy body disease, frontotemporal...
- Has symptoms of agitation that are not secondary to Alzheimer's disease (eg, pain, other psychiatric disorder, or delirium due to a metabolic...
- Participant (or caregiver) is deemed otherwise ineligible for participation in this study in the investigator's judgement.
The study team makes the final eligibility decision.
Where it's taking place
- Anaheim, California, United States
- Costa Mesa, California, United States
- Encino, California, United States
- Fresno, California, United States
- Fullerton, California, United States
- Los Angeles, California, United States
- Stamford, Connecticut, United States
- Miami, Florida, United States
- Orlando, Florida, United States
- Pompano Beach, Florida, United States
- Chicago, Illinois, United States
- Toms River, New Jersey, United States
- Amherst, New York, United States
- East Syracuse, New York, United States
- Beachwood, Ohio, United States
- Charleston, South Carolina, United States
- Columbia, South Carolina, United States
- Beaumont, Texas, United States
- Fort Worth, Texas, United States
- Houston, Texas, United States
+ 11 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years to 90 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Anaheim, California, United States; Costa Mesa, California, United States; Encino, California, United States; Fresno, California, United States; Fullerton, California, United States; Los Angeles, California, United States and 25 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.